Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing`s Disease

Study:

A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) sc Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing`s Disease

Rationale:

n/a

Purpose:

This study will evaluate the safety and efficacy of two different doses of Pasireotide in patients with de novo or recurrent/persistent Cushing`s Disease.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Cushing`s Disease Drug: Pasireotide Phase 3

Verified by Novartis Pharmaceuticals July, 2013

Sponsored by: Novartis Pharmaceuticals
Information provided by: Novartis
ClinicalTrials.gov identifier: NCT00434148

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic Foundation Dept. of Cleveland Clinic (6)
Cleveland, Ohio 44195
United States

Novartis Pharmaceuticals., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site